Endogenous opiate peptides acting pre-and post-synaptically in the dorsal horn of spinal cord inhibit transmission of nociceptive stimuli. We transfected neurons of the dorsal root ganglion in vivo by footpad inoculation with 30 l (3 × 10 7 p.f.u.) of a replication-incompetent (ICP4-deleted) herpes simplex virus (HSV) vector with a cassette containing a portion of the human proenkephalin gene coding for 5 metand 1 leu-enkephalin molecules under the control of the human cytomegalovirus immediate-early promoter (HCMV IEp) inserted in the HSV thymidine kinase (tk) locus. Vectordirected expression of enkephalin produced a significant
Introduction
The pharmacologic activity of opiate drugs corresponds to the distribution of endogenous opioid peptides and their receptors in the nervous system. 1, 2 One important location for the action of opioids is the dorsal horn of spinal cord where opioid receptors are found on both spinal interneurons and on the terminals of the primary afferent nociceptors whose cell bodies are in the dorsal root ganglia (DRG). 3, 4 In vitro opioids produce a direct inhibitory effect on the electrical activity of spinothalamic projection neurons of dorsal horn or trigeminal nucleus, [5] [6] [7] and act presynaptically to inhibit release of neurotransmitter from DRG neurons. [8] [9] [10] [11] Intrathecal administration of morphine inhibits the release of substance P by the primary afferent nociceptor in vivo, 12 which correlates with the efficacy of intrathecal opiates that are used in clinical applications.
More than 20 endogenous opioid peptides have been identified, most of which share the N-terminal sequence of Tyr-Gly-Gly-Phe-Met or Tyr-Gly-Gly-Phe-Leu; they are produced as the cleavage products of three distinct precursors that have been termed proenkephalin A, prodynorphin, and proopiomelanocortin. 13, 14 Proenkephalin A is the only opioid peptide precursor in spinal cord, where the gene is expressed primarily in interneurons in antinociceptive effect measured by the formalin footpad test, that was most prominent in the delayed ('tonic') phase 20-70 min after the administration of formalin. The magnitude of the antinociceptive effect diminished over 4 weeks after transduction, but reinoculation of the vector reestablished the analgesic effect, without evidence for the development of tolerance. The antinociceptive effect was blocked completely by intrathecal naltrexone. These results suggest that gene therapy with an enkephalin-producing herpes-based vector may prove useful in the treatment of pain. Gene Therapy (2001) 8, 551-556.
the dorsal horn and the product cleaved to produce metand leu-enkephalin. It is presumed that the pre-and postsynaptic anti-nociceptive effects of opiate drugs described above result from activation of the same opioid receptors that respond to endogenous production and release of met-and leu-enkephalin.
Gene transfer represents a novel means to express identified transgenes in specific locations in the nervous system, and herpes simplex virus-based vectors have a special utility for primary sensory neurons. Wild-type HSV is a neurotropic double-stranded DNA virus that, following primary infection of epithelium, is carried by retrograde axonal transport to the dorsal root ganglion (DRG) where the viral genome may establish a life-long latent state. [15] [16] [17] Because HSV genes involved in viral replication are expressed in a rigid temporal cascade, deletion of essential immediate-early (IE) genes from the HSV genome allows the creation of a vector that is incapable of replicating in normal tissue in vivo, but nonetheless is capable of the efficient establishment of a quiescent state that is similar to natural viral latency but without the potential for reactivation. 18, 19 We have previously demonstrated that genomic HSV-based vectors can be employed to express biologically active nerve growth factor 20 and the anti-apoptotic peptide Bcl-2 21 in vitro and in vivo.
In the experiments described in this report, we tested the ability of a genomic HSV vector expressing enkephalin to produce an antinociceptive effect in rats. We constructed a replication-incompetent genomic HSV vector deleted for the essential IE gene ICP4, with the proen-kephalin coding sequence under the control of the human cytomegalovirus immediate-early promoter (HCMV IEp) element in the viral tk locus, and used that vector to transfect neurons of the rat lumbar DRG by foot-pad inoculation. We demonstrate that this vector produces an antinociceptive effect, significantly reducing nocifensive behavior in the delayed 'tonic' phase after the subcutaneous administration of formalin.
Results
Inoculation of the footpad with the non-replicating vector SHPE resulted in transduction of lumbar DRG and expression of proenkephalin mRNA. Using primers specific for the human proenkephalin sequence to amplify a 248 bp fragment of the human gene insert (Figure 1a) , we found specific bands from all four SHPE-injected rats killed 1 week after inoculation (Figure 1b Expression of the human peptide in transfected neurons was assessed in vitro. Mouse DRG neurons transfected with SHPE expressed human PE detected by immunocytochemistry, while DRG neurons transfected with the control SHZ vector showed only background immunofluorescence similar to uninfected neurons ( Figure 2 ). We were not able to identify the peptide in vivo by immunofluorescence (data not shown).
Injection of dilute formalin subcutaneously into the footpad of control animals caused the rats to exhibit nocifensive behaviors as previously described, 22 with an immediate pain response (at time 0), a period of normal behavior (observed at 10 min after formalin injection), followed by a characteristic increasing and than decreasing pain response lasting over 60 min (Figure 3a , control curve -filled circles). Rats injected with SHPE 1 week before formalin testing showed a significant reduction in nocifensive behaviors at 30, 40, 50, 60, and 70 min after formalin injection (Figure 3a , black squares). The antinociceptive effect of the vector was reversed by an intrathecal injection of naltrexone (20 nmol) administered 5 min before the injection of formalin (Figure 3e , gray squares). Intraperitoneal injection of naloxone (50 mg/kg) also reversed the effect of the vector (data not shown). Because injection of formalin may cause long-lasting alterations to the subcutaneous tissue each animal was tested only once, and the naltrexone experiments were performed on a different set of animals than the 1 week test group.
Rats inoculated with SHPE 2 weeks before formalin testing showed a less pronounced antinociceptive effect that was statistically significant only at 20, 30 and 60 min after formalin (Figure 3b , black squares). The reduction in response to the vector is consistent with previous observations regarding the time-course of transgene expression by HSV vectors utilizing the HCMV IEp to drive transgene expression. 23, 24 Rats injected with SHPE 4 weeks before formalin testing showed a quantitatively smaller response to the vector, with statistically significant differences only at 60 min after formalin (Figure 3c , black squares). We had anticipated that the response to vector transduction would be severely attenuated by 28 days, and for that reason had inoculated those animals in both the left and right rear footpads at the time of initial vector inoculation. After formalin testing in the left footpad, as described above
Figure 2 Immunofluorescent detection of human PE in DRG neurons transfected with SHPE in vitro (A). Neurons transfected with the lacZexpressing control vector SHZ demonstrate only background immunofluorescence (B). The photomicrographs shown were taken with identical exposures, chosen to show the control vector-infected cells (B) which were identical to uninfected neurons (data not shown).

Figure 3 Weighted pain score following injection of dilute formalin in SHZ inoculated control animals (circles) and SHPE inoculated animals (squares) at 7 days (a), 14 days (b), 28 days (c), and 35 days in animals reinoculated 7 days before testing (d). Intrathecal naltrexone reversed the antinociceptive effect in animals tested 7 days after SHPE inoculation (e). A cumulative pain score, representing the sum of the weighted pain scores from 20 to 70 min, demonstrates the time-course of the antinociceptive effect of the vector (f). The number of animals in each group is shown in parentheses. The same control group is shown in all graphs.
and shown in Figure 3c , we reinoculated the same rats in the right footpad with SHPE (identical to the initial inoculation), and retested the animals with an injection of formalin into the right footpad 1 week later (35 days after the initial vector inoculation, 7 days after reinoculation).
Formalin testing in the right (reinoculated) footpad at 35 days showed that a robust antinociceptive response, which was statistically significant at 30, 40, 50, 60 and 70 min after formalin, had been reestablished (Figure 3d , open squares). Separate control animals (those inoculated with the SHZ vector) were tested at the same time as SHPE inoculated animals at each time-point, however, all control animals were grouped together for statistical comparison to SHPE inoculated animals, and that control curve is reproduced in each panel of Figure 3a -e (black circles).
The relative reduction in nocifensive behavior at the several different times after vector inoculation is shown in Figure 3f , where we have plotted a cumulative pain score representing the sum of the scores at the 20 to 70 min intervals for each of the times after vector inoculation. The cumulative pain score illustrates the significant reduction in nocifensive behavior at 7 days after vector inoculation, the reduction in that effect in animals inoculated 2 or 4 weeks before testing, and the reestablishment of the response by reinoculation.
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Discussion
The data presented in this report demonstrate that a nonreplicating genomic HSV-based vector engineered to express proenkephalin can be used to transduce primary sensory neurons of the DRG to produce a analgesic effect in rats. The formalin test 22 allows the observation of nocifensive behaviors in unrestrained animals over a prolonged period of time. Human subjects describe the pain caused by formalin injection as an initially intense, sharp or stinging sensation that gives way to a steady throbbing ache that gradually disappears over 1 h. 22 The response recorded in the 'tonic' phase in animals corresponds to that steady throbbing ache, in contrast to acute pain sensation.
This report substantially extends the observations of Wilson and colleagues 25 who used a replicating herpes vector, KHPE, to deliver the same gene product to the DRG by subcutaneous injection into the dorsum of the foot in mice. While no primary antinociceptive effect of the vector was observed in those experiments, enkephalin production by the vector resulted in an antihyperalgesic effect that was demonstrated by an increased latency to withdraw the foot from noxious heat after sensitization of C-fibers by application of capsaicin, or sensitization of A␦ fibers by application of dimethyl sulfoxide. 25 Foot withdrawal to noxious radiant heat before sensitization is an acute pain response which in its timecourse correlates with the nociceptive behavior in the formalin test immediately after injection of formalin. In agreement with Wilson's study, the response to formalin immediately after injection was not altered by inoculation with vector SHPE in our experiments. The antinociceptive effect we observed in the tonic phase after formalin injection following inoculation with SHPE represents an analgesic effect in a well-established model of inflammatory pain and extends the potential utility of gene transfer for treatment of pain.
The second major difference between these studies and the previous report is the nature of the vector. KHPE 25 is a replication-competent herpes virus that presumably replicates in epithelial cells following inoculation and before axonal transport. SHPE (the current report) is a replication-incompetent mutant that despite not dividing in the epithelium nonetheless efficiently transfects the DRG. This is an important consideration for potential therapeutic application. The difference between their use of a replicating HSV vector and our use of a non-replicating vector may be one explanation for the fact that they were able to detect the gene product by immunocytochemistry in vivo, whereas we were unable to do so. Unfortunately, the antibody they used for their studies is no longer available, so that direct comparison of their immunochemical results with our results is not possible. Nonetheless, using a similar antibody specific for the human peptide, we have demonstrated expression of the peptide product in transfected cells in vitro, and the RT-PCR data provides specific evidence in our studies for expression of the human transgene in transfected DRG neurons in vivo. We found that the antinociceptive effect was maximal at 1 week after inoculation. This timecourse is also different than the time course reported by Wilson et al. We believe it is likely that the difference in time-course is due to differences in the models tested, as in preliminary studies we have found a different time-course of antinociceptive effect of the same vector in a model of neuropathic pain (data not shown).
These experiments differ substantially from other gene transfer approaches that have between reported previously. An adenoviral vector expressing the ␤-endorphin coding sequence infused intrathecally in rats has been reported to attenuate the hyperalgesic response in the carageenan model of inflammatory pain 26 but had no effect on the latency to withdraw a non-inflamed paw from radiant thermal heat. Transgene expression from the adenoviral vector appeared to be limited to the pia mater, with release of ␤-endorphin into the cerebrospinal fluid. 26 In contrast, HSV-mediated gene transfer results in specific transfection of primary sensory neurons in the DRG. The mechanism of adenoviral gene transfer is more like cell transplantation studies which have been reported. For example, retrovirus vectors have been used to transfect and express ␤-endorphin in fibroblasts, 27 and spinal transplantation of adrenal medullary cells which naturally release opioid peptides reduces nocifensive behaviors (tail flick and paw pinch response) 28 and have been reported to decrease experienced pain in humans with pain and terminal cancer; 29 similar results have been demonstrated using the AtT-20 pituitary tumor-derived cell line modified to constitutively secrete enkephalin. 30, 31 However, these approaches all rely on release of peptides into CSF, rather than localized release of enkephalin in the dorsal horn.
We presume that release of the HSV-mediated opiate peptides occurs from the central terminal of primary afferent neurons in the dorsal horn of spinal cord. While we have not identified the specific neurons that harbor the latent HSV genomes, there is no reason to expect that the vector should show a preference for nociceptors. Because A␦ and C fibers typically constitute 70-80% of nerve fibers innervating the skin 13 it is not unlikely that a substantial proportion of the transduced neurons project to the superficial layers of dorsal horn. Even release of transgene-coded enkephalin by non-nociceptive afferents would release the peptide in the near vicinity of the second order neuron in the spinal cord. We have previously demonstrated in vitro that an HSV vector transgene-coded peptide (NGF) is appropriately processed and released from neurons in vitro. 20 The affinity of enkephalins for opiate receptors is roughly half that of morphine, yet following direct injection in vivo, met-enkephalin is more than one order of magnitude weaker than morphine as an analgesic, 32 and the analgesic effect of the peptide is short-lived; 33 both of these phenomena result from the distribution of an endogenous neutral protease 'enkephalinase' 34 in the same distribution as endogenous opiates and their receptors. One potential advantage of gene transfer to primary sensory neurons is that continuous local release of an opiate peptide in the spinal cord may avoid some of the problems that result from the central actions of systemic or intrathecal administration of opiate drugs. 35 Is it possible that the biological effect of released vector-encoded enkephalin is mediated through actions at peripheral, rather than the central terminal of the sensory neuron? 36 Mu, delta and kappa opioid receptors have been demonstrated on the peripheral terminals of sensory axons, 37, 38 and the peripheral injection of opioid drugs relieves inflammatory pain in animal models. 38, 39 However, intrathecal injection of naltrexone completely reversed the analgesia produced by the vector supporting the interpretation that the analgesic effect occurs at the level of the spinal cord rather than peripherally. In fact, animals that received naltrexone demonstrated a significantly higher cumulative tonic pain score than control animals, which may have resulted from block of endogenous opioid effects in addition to block of vectorexpressed enkephalin. We also have no direct evidence regarding the development of tolerance in this model. However, the loss of effect over several weeks parallels the known time-course of expression of transgenes from the HSV vector in neurons using the HCMV promoter, 17, 23 and the reestablishment of an antinociceptive effect by reinoculation also suggests that tolerance had not developed.
There are several potential avenues of investigation that may be developed from the observations reported here. We do not know if the antinociceptive effect of the enkephalin vector is specific for inflammatory pain, of the sort modeled by the formalin test, or whether similar effects can be achieved in models of neuropathic pain or pain caused by cancer. We will need to determine if the duration of the analgesic effect can be extended by employing a vector that uses the HSV latency-active promoter element to drive enkephalin expression. 40 It will also be of interest to determine whether coexpression of other gene products from the same vector may improve the analgesic potency of the vector. However, the results of the current experiments, demonstrating that a non-replicating genomic HSV-based vector expressing proenkephalin provides an antinociceptive effect in rats, is an important proof of principle demonstration of a novel analgesic therapeutic modality.
Materials and methods
Vector construction
The vector SHPE (Figure 1a ) was constructed as previously described. 25 A cassette containing the HCMV IEp, SV40 intron, human proenkephalin cDNA and SV40 polyadenlyation sequence 41 was cloned into a plasmid (pBluescript II SK; Stratagene, La Jolla, CA, USA) containing a lox P site, and inserted into the tk locus of the ICP4-deleted HSV vector d120k-lox, a modified version of d120 42 that was previously engineered to contain a loxP site at the tk locus, 43 by cre-lox recombination. 44 This vector contains only the proenkephalin PE transgene, without other reporter transgenes. The control vector SHZ 43 was identical to SHPE except that the inserted cassette contained the E. coli lacZ reporter gene under the control of the HCMV IEp in the tk locus. Both the PE and control vector were isolated by three rounds of limiting dilution, and the final vector purified at 1 × 10 9 p.f.u./ml.
Immunocytochemical determination of enkephalin expression DRG from 17-day rat embryos were dissociated with 0.25% trypsin-1 mm EDTA for 30 min at 37°C with constant shaking and then plated on poly-d-lysine-coated coverslips at 10 5 cells per well in a 24-well plate in 500 l of defined Neurobasal media suplimented with 1 × B027, 1 × GlutaMAX, 0.5 g AlbuMAX II (Gibco-BRL, Rockville, MD, USA) per ml, 100 U of penicillin per ml, and 100 ng of 7.0s NGF per ml (Sigma, St Louis, MD, USA).
Fourteen days after plating the cells were infected with either vector SHPE or vector SHZ at a multiplicity of infection (MOI) of 1 for 1 h, washed in fresh media, and incubated overnight. The cells were then washed and placed in fresh media containing 1 mm colchicine (Sigma) and incubated for 2 h, after which they were fixed in Histochoice (Amresco, Solon, OH, USA) for 20 min at room temperature. Enkephalin, produced by vector SHPE, was detected using an anti-enkephalin primary antibody (Pennisula Laboratories, Belmont, CA, USA) at 1:200 in PBS containing 1% goat serum, incubated overnight at 4°C and visualized using a Cy3-conjugated anti-rabbit secondary antibody (Sigma).
Vector inoculation
Male Wistar rats (Charles River, Boston, MA, USA) weighing 225-250 g were used for these experiments. The animals were anesthetized with chloral hydrate (400 mg/kg) and 30 l containing 3 × 10 6 p.f.u. of either SHPE or SHZ was injected subcutaneously under the skin on the plantar aspect of one or both rear paws.
Tissue analysis of transgene expression
One week after vector inoculation, a subset of rats was killed, the DRGs were removed, frozen on dry ice, and stored at −80°C. DNA was isolated from the DRGs of four SHPE and three SHZ injected rats using a Qiagen kit according to the manufacturer's instructions (Valencia, CA, USA). A 248 bp fragment of human PE was amplified (94°C for 45 s, 63°C for 45 s, 72°C for 1.5 min, 40 cycles) using the primers 5Ј-AGAGGCCAATGG AAGTGAGA-3Ј (forward) and 5Ј-CAGCTCTTTGG CTTCATCT-3Ј (reverse), a RoboCycler (Stratagene), and Perkin-Elmer (Foster City, CA, USA) Amplitaq Gold enzyme (20 l total reaction volume, consisting of 0.2 mm dNTPs, 10 pm primers, and 0.5 unit of Taq polymerase). The PCR products were separated on a 1.5% agarose gel containing ethidium bromide.
Total RNA was extracted from the DRGs of three SHPE transfected rats using TriReagent (Sigma). Approximately 1 g of DNaseI-treated or untreated total RNA was used to synthesize cDNA using a GeneAmp Kit (Perkin Elmer). A 248 bp fragment of human PE was amplified as described above except that the reaction mixture contained 0.67 m 32 P-dCTP (3000 Ci/mmol), the products separated on a 6% polyacrylamide gel, and visualized by autoradiography using Kodak (New Haven, CT, USA) X-OMAT film.
Formalin test
Nociception was evaluated by quantitation of nocifensive behavior using the formalin footpad test. 22 A dilute solution of formalin (2.5%) was injected subcutaneously in the plantar aspect of the same foot that had received the viral inoculation, and the rats then placed into a 48 × 27 × 20 cm plastic box positioned over a mirror tilted at a 45°angle. Beginning 30 s after the injection of formalin, and once every 10 min thereafter, nocifensive behaviors were recorded by a blinded observer for 3 min; a weighted pain score was derived based on the amount of time the animal exhibited each behavior during the 3 min period of observation. 22 The weighted pain score was plotted against time, and compared between control and treatment groups using a one-way ANOVA. Each animal was tested only once with formalin. There were Gene Therapy 17 animals in the control group, 10 animals in the group tested 1 week after vector inoculation, nine animals in the group tested 2 weeks after vector inoculation, five animals in the group tested at 4 weeks and five animals in the group that was reinoculated at 4 weeks and tested 1 week later. Three animals were tested with intrathecal naltrexone.
Intrathecal injection
The site of action of HSV-mediated analgesia was assessed through intrathecal injection of naltrexone in rats inoculated with either SHPE or SHZ. Seven days following vector inoculation, rats were injected with 20 nmol of naltrexone (Sigma) in sterile 0.9% saline via direct transcutaneous injection between the dorsal aspects of L5 and L6. 45 Five minutes later, nocifensive behavior was evaluated using the formalin test.
